|
eGFR (mL/min/1.73 m2)
|
---|
≧90 | ≧60 to <90 | ≧30 to <60 |
P value
|
---|
Number of subjects
|
99
|
525
|
228
| |
All adverse events
|
82 (82.8%)
|
462 (88.0%)
|
198 (86.8%)
|
0.3609*
|
gastrointestinal symptoms–relate adverse events
|
33 (33.3%)
|
192 (36.6%)
|
88 (38.6%)
|
0.6631*
|
Abdominal pain upper
|
4 (4.0%)
|
31 (5.9%)
|
7 (3.1%)
|
NT
|
Constipation
|
4 (4.0%)
|
37 (7.0%)
|
19 (8.3%)
|
NT
|
Diarrhoea
|
4 (4.0%)
|
17 (3.2%)
|
12 (5.3%)
|
NT
|
Stomach discomfort
|
11 (11.1%)
|
44 (8.4%)
|
14 (6.1%)
|
NT
|
Urinary- and kidney function-related adverse events
|
2 (2.0%)
|
11 (2.1%)
|
7 (3.1%)
|
0.6295*
|
Osteonecrosis of the jaw
|
0 (0.0%)
|
0 (0.0%)
|
0 (0.0%)
|
NT
|
Atypical femoral fractures
|
0 (0.0%)
|
0 (0.0%)
|
0 (0.0%)
|
NT
|
-
NT not test
- * Fisher’s exact test